BCMA

News

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.

News

Regeneron gets long-awaited FDA okay for myeloma drug

Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised.

News

Japan follows UK in GSK's comeback tour for Blenrep

The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.

News

Survival data graph from the DREAMM-7 trial

ASH: Blenrep ups survival by 42% in multiple myeloma trial

GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.

News

GSK files Blenrep in EU, seeking return to market

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc

News

Carvykti, Abecma move earlier in multiple myeloma treatment

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one pri

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Regeneron gets long-awaited FDA okay for myeloma drug

Japan follows UK in GSK's comeback tour for Blenrep

ASH: Blenrep ups survival by 42% in multiple myeloma trial

GSK files Blenrep in EU, seeking return to market

Carvykti, Abecma move earlier in multiple myeloma treatment

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

BCMA

Editor's Picks